Merger Review and Second Requests: HSR Timing, Substantive Analysis, and Remedies

Document type: Article Practice area: Corporate — Antitrust Jurisdiction: United States (federal) Last reviewed: 5 September 2026

Where merger cases are actually won

Not in the second request response, and not at trial. They are won — or lost — in the eighteen months before signing, in the ordinary-course documents that executives write about competitors, pricing, and why the deal makes sense.

An agency reviewing a merger reads the parties' own strategic plans, board presentations, deal models, and emails. If those documents say the target is the only serious constraint on the acquirer's pricing, no economist will persuade the agency otherwise. If they describe a fragmented market, a dozen credible alternatives, and a rationale grounded in capability rather than competition, the analysis starts from a very different place.

Everything else in this article is downstream of that.

The substantive standard

Section 7 of the Clayton Act, 15 U.S.C. § 18, prohibits an acquisition of stock or assets where, in any line of commerce or in any activity affecting commerce in any section of the country, the effect of the acquisition may be substantially to lessen competition, or to tend to create a monopoly.

Three features of that text drive everything.

It is prospective and probabilistic. "May be" requires a reasonable probability of anticompetitive effect, not a certainty and not a completed harm. That is a materially lower threshold than the conduct offenses in Sherman Act §§ 1 and 2, and it is why merger challenges are brought before consummation rather than after.

It is market-specific. Harm in any line of commerce in any section of the country is enough. A national transaction can be challenged because of an overlap in a single metropolitan area or a single product niche — which is why the diligence question is never "is this deal problematic" but "where does it overlap, and how much."

It reaches incipient harm. Section 7 was intended to arrest anticompetitive tendencies in their incipiency, which is the doctrinal basis for challenging transactions that would not violate the Sherman Act.

Enforcement authority is shared. The Department of Justice may sue under 15 U.S.C. § 25, and the Federal Trade Commission proceeds administratively and may seek a preliminary injunction under 15 U.S.C. § 53(b). Private parties may seek injunctive relief under 15 U.S.C. § 26, and state attorneys general are increasingly active — a fact deal teams routinely underweight.

And the antitrust injury requirement constrains private challenges. Brunswick Corp. v. Pueblo Bowl-O-Mat, Inc., 429 U.S. 477 (1977) held that a plaintiff must prove injury of the type the antitrust laws were intended to prevent and that flows from that which makes the defendants' acts unlawful — a competitor complaining that a merger will make a rival more efficient has not stated an antitrust injury.

How the agencies actually analyze a merger

Market definition comes first in the traditional framework, though modern practice increasingly treats direct evidence of competitive effects as sufficient without a precisely defined market. The product market asks what the customer would substitute to; the geographic market asks where the customer would go. The hypothetical monopolist framework — would a small but significant non-transitory increase in price be profitable for a hypothetical monopolist of the candidate market — supplies the analytical discipline.

Concentration is measured by market shares and the Herfindahl-Hirschman Index, with thresholds that create structural presumptions. A transaction that produces a highly concentrated market and a significant increase in concentration draws a presumption of harm the parties must rebut. Agency thresholds have tightened, and merger guidelines are revised periodically — check the operative version.

Unilateral effects ask whether the merged firm alone would find it profitable to raise price or reduce quality, because sales diverted from one merging party would be recaptured by the other. This is the dominant theory in differentiated product markets, and diversion ratios and margins do most of the work.

Coordinated effects ask whether the transaction makes tacit or explicit coordination among remaining firms more likely, more complete, or more durable — by removing a maverick, increasing transparency, or reducing the number of significant competitors.

Entry and expansion can rebut a prima facie case, but only if entry would be timely, likely, and sufficient to counteract the harm. Vague assertions that "the market is dynamic" do not qualify.

Efficiencies may rebut, and the standard is demanding: they must be merger-specific (not achievable without the transaction), verifiable (not projections prepared for the agency), and passed through to consumers rather than retained. In practice efficiencies rarely carry the day alone, though they matter at the margin and in remedy discussions.

The failing firm defense exists and is narrow: imminent failure, inability to reorganize, unsuccessful good-faith efforts to find an alternative purchaser posing a less severe competitive threat, and assets that would otherwise exit the market. United States v. General Dynamics Corp., 415 U.S. 486 (1974) is the companion authority for the broader proposition that market share statistics can be rebutted by evidence about a firm's actual future competitive significance — there, coal reserves already committed under long-term contracts made past production shares a poor proxy for future competitive strength.

Vertical and conglomerate theories

Horizontal overlaps are the core, but the agencies have pressed non-horizontal theories with increasing frequency, and deal teams that screen only for overlaps miss the risk.

Foreclosure and raising rivals' costs. A vertical combination may give the merged firm the ability and incentive to withhold an input from downstream rivals, or to degrade access, or to raise the price. The analysis asks whether the firm would have the ability to foreclose (is the input important and are alternatives poor), the incentive (is downstream profit gained greater than upstream profit lost), and whether the effect would be substantial.

Access to competitively sensitive information. A supplier that acquires a downstream competitor gains visibility into rivals' orders, forecasts, and specifications, which can soften competition even without foreclosure. This theory has driven several recent challenges and is frequently addressed by firewall commitments the agencies view skeptically.

Elimination of potential competition, actual or perceived — the acquisition of a nascent competitor that would have grown into a constraint, or whose presence at the edge of the market disciplines the incumbent. This theory is doctrinally contested and is a live area in technology and pharmaceutical acquisitions.

Serial acquisitions. A pattern of small transactions, each individually unremarkable, assessed cumulatively. Deal teams should assume the agency will look at the whole roll-up.

The procedure: waiting periods and second requests

Section 7A of the Clayton Act, 15 U.S.C. § 18a — the Hart-Scott-Rodino Act — requires notification and observance of a waiting period before consummating a reportable transaction. The rules are at 16 C.F.R. Parts 801 and 803, which govern coverage and procedure respectively.

The initial waiting period is 30 days for most transactions and 15 days for cash tender offers and certain bankruptcy acquisitions. Early termination may be available depending on agency practice at the time.

Clearance between the agencies happens in the first days: the FTC and the Antitrust Division determine which will review the transaction, based on industry expertise and history. Which agency takes it matters — their procedures, their remedy practices, and their litigation postures differ.

Pull and refile. A party may withdraw its notification and refile, restarting the initial waiting period once, without a new fee. This is a standard device: it buys the agency 30 more days when it is not ready to decide, in exchange for not issuing a second request. Parties agree to it routinely, and refusing invites the second request the withdrawal would have avoided.

The second request — formally a request for additional information and documentary material under § 18a(e) — extends the waiting period until 30 days (10 for cash tender offers) after both parties substantially comply. It is not a discovery request in the litigation sense; it is broader, and compliance is the party's own obligation to certify.

What a second request demands. Documents from a defined set of custodians over a multi-year period; narrative interrogatory-style responses about the business, the markets, and the transaction; extensive transactional and financial data; and, frequently, structured data productions that require the company's analysts as much as its lawyers.

What compliance costs. For a substantial transaction, the response commonly involves dozens of custodians, millions of documents, months of review, and a budget in the millions. The single largest variable is the negotiated custodian count and date range.

The certification of substantial compliance is the pivotal event: it restarts a 30-day clock, and it is the parties' own certification. Certifying too early invites a challenge to compliance; certifying late delays the deal.

A running example

Halloran Instrument manufactures benchtop analytical instruments and holds roughly 34% of the United States market for a particular class of spectrometer. It agreed to acquire Vellacott Scientific, which holds about 21% of the same market. Four other competitors share the remainder, the largest at 18%.

Halloran's general counsel is Miriam Oyelaran-Fitzgerald. Her outside antitrust counsel gave her the assessment on day two: on those shares, in a differentiated product market with meaningful diversion between the two, this transaction draws a second request and probably a demand for a divestiture.

The pre-signing document assessment. Counsel searched twelve likely custodians for the predictable themes. It found three problems: a 2024 strategic plan describing Vellacott as "the principal obstacle to list-price discipline"; a deal model with a synergy line labeled "pricing uplift, post-consolidation"; and an email from a sales vice president saying "once we own them we can stop matching their quotes."

None of those documents was created to describe a violation. All three read as admissions. Halloran could not unwrite them, and did not try. What it did instead was build the explanation: the pricing uplift line was a modeling placeholder that the finance team could document as never having been validated; the "principal obstacle" language described a specific product tier in which two other competitors also competed; and the sales email's author had no role in pricing decisions. Counsel prepared the context before filing rather than after production.

The filing and the first thirty days. Filed with the documents that 16 C.F.R. Part 803 requires with the notification. Clearance went to the Antitrust Division. On day 28 the Division asked the parties to pull and refile. They agreed, buying the agency 30 more days and themselves a chance to persuade before a second request issued.

It issued anyway. Custodians demanded: 41. Date range: five years. Data specifications covering transaction-level pricing for the entire period.

The negotiation that mattered. Over three weeks counsel reduced custodians from 41 to 17, narrowed the date range for most categories to three years, agreed search terms and a technology-assisted review protocol, and staged the production. That negotiation saved an estimated $4 million and two months.

The substantive campaign, run in parallel. An economic submission on diversion ratios showing that a meaningful share of sales lost by either party would go to the two mid-sized competitors rather than to each other. Twelve customer interviews, of which nine said they routinely qualified at least three vendors. And a documented analysis of two recent entrants.

The remedy. The Division was not persuaded on the highest-resolution tier, where the parties were genuinely the leading two. Halloran proposed divesting Vellacott's product line in that tier, together with the associated intellectual property, three engineers, the customer list, and a two-year supply agreement — to an identified upfront buyer, a European instrument maker seeking United States entry.

The outcome. A consent decree, entered after the statutory comment period, eleven months after signing. Total antitrust cost: about $14 million, of which roughly $9 million was second request compliance.

Oyelaran-Fitzgerald's assessment: "The deal survived because we found our own bad documents in month one and because the divestiture package was a real business with a real buyer. The three weeks we spent negotiating the custodian list paid for the entire rest of the process."

Timing agreements, and why the statutory clock is not the real one

The waiting period in § 18a describes a process that no longer resembles practice in a contested review.

The timing agreement is a negotiated arrangement in which the parties agree not to close for a specified period after certifying substantial compliance — commonly 60 to 90 days rather than the statutory 30 — and agree to advance notice before closing, in exchange for the agency's commitment to a schedule of engagement, meetings, and a decision.

Why parties agree. An agency that has not finished its analysis when the clock expires will simply sue to preserve the status quo. A timing agreement converts a litigation deadline into a negotiation schedule, and it buys the opportunity to persuade.

What to negotiate in it: the length of the post-certification period; the number and timing of substantive meetings; access to the front office and the decision-makers; commitments about data and economic submissions; and the notice period before closing.

And what it costs. Months. A contested review with a second request and a timing agreement routinely runs a year or more from signing, which is why merger agreements need outside dates, financing that survives them, and provisions addressing what happens to the business in the meantime.

Gun jumping is the other timing constraint. Until the waiting period expires, the parties remain independent competitors, and coordination is unlawful under § 18a and potentially Sherman Act § 1. Integration planning must proceed through a clean team with defined protocols; competitively sensitive information — current pricing, customer-specific terms, forward plans — does not move between the parties; and the buyer does not direct the seller's ordinary-course conduct. Interim operating covenants in the merger agreement should be drafted with this in mind, and the practical enforcement problem is the business teams' enthusiasm, not the lawyers' understanding.

Remedies

Most transactions the agencies would otherwise challenge are resolved by a remedy, and the strong preference is structural.

Structural relief — divestiture — is preferred because it restores an independent competitor without requiring ongoing supervision. The agencies assess:

Scope. Is the divestiture package a standalone, viable business — with the manufacturing, intellectual property, personnel, customer relationships, and supply arrangements it needs? A package assembled to minimize what the parties give up frequently fails this test.
The buyer. Is the proposed purchaser financially capable, experienced, and independent, with the incentive and ability to compete? An upfront buyer — identified and approved before the merger closes — is frequently required, and is the difference between a remedy that works and one that produces a failed divestiture the agency will remember for a decade.
Transitional support. Supply agreements, transition services, and technology licenses may be necessary and are also a source of ongoing entanglement the agencies dislike.
Crown jewel provisions, requiring a larger divestiture if the first is not completed.

Behavioral or conduct remedies — firewalls, non-discrimination commitments, supply obligations, arbitration mechanisms — are viewed with skepticism, particularly for horizontal overlaps. They require ongoing monitoring, they ask the agency to regulate rather than restore competition, and their enforcement record is mixed. They appear most often in vertical matters, and even there their acceptance varies with enforcement policy.

The consent decree machinery. Department of Justice settlements are entered as consent judgments subject to public comment and judicial review under the Tunney Act; FTC settlements proceed through a consent order with a public comment period. Both include monitoring, reporting, and compliance obligations that outlast the deal team.

The practical advice. Bring a remedy proposal to the agency before it has committed to a challenge, with a package that is genuinely viable and a buyer that is genuinely capable. A late, thin proposal offered as an alternative to litigation is usually declined — and the offer itself signals that the parties know the deal has a problem.

Litigation, if there is no remedy

The postures differ by agency. The Department of Justice sues in federal district court under 15 U.S.C. § 25 seeking to enjoin the transaction. The Federal Trade Commission typically seeks a preliminary injunction in district court under 15 U.S.C. § 53(b) while an administrative proceeding runs in parallel before its own tribunal.

The practical consequence is that an FTC preliminary injunction, even if the administrative case would later go the parties' way, usually kills the deal — because financing, employees, and customers do not survive the delay. Merger litigation is nearly always effectively final at the preliminary injunction stage.

The trial is fast and expert-heavy. These cases are tried in months, not years, on a record built from ordinary-course documents, executive testimony, customer testimony, and competing economic models. Customer witnesses matter enormously: a purchaser who credibly testifies that the merging parties are its only two options is worth more than any regression.

The burden framework. The government establishes a prima facie case, commonly through market definition and concentration statistics; the burden shifts to the defendants to rebut; and the ultimate burden of persuasion remains with the government. General Dynamics is the paradigm rebuttal case, and its lesson — that structural statistics can be shown to misdescribe actual competitive significance — is the template for every defense.

Litigating the fix. Where the parties have proposed a divestiture the agency rejected, they may litigate the transaction as modified. Whether the court evaluates the deal with or without the proposed remedy is contested and consequential.

And the decision to litigate is a business decision. It costs many millions, takes a year or more, and requires the target to remain in limbo. Sellers and buyers experience that period very differently, which is why the allocation of antitrust risk in the merger agreement is negotiated so hard.

Allocating antitrust risk in the agreement

The provisions that matter, and they are negotiated before anyone knows whether there will be a problem.

The efforts covenant. The spectrum runs from "commercially reasonable efforts" through "reasonable best efforts" to a "hell or high water" covenant obligating the buyer to take any action — including divestitures and litigation — necessary to obtain clearance. Between them sit negotiated caps: a divestiture obligation limited to assets generating up to a stated revenue amount, or an obligation to litigate but not to divest beyond a threshold.

The outside date, with automatic extensions tied to regulatory review, and the number of extensions.

The reverse termination fee payable by the buyer if the deal fails on antitrust grounds — the seller's compensation for the exclusivity and the disruption. Sizing this is the negotiation, and it is frequently the number that allocates the risk in substance.

Interim operating covenants, drafted to preserve the business without gun jumping.

Control of the regulatory process: who leads, who attends meetings, who approves submissions, and what the seller's information and consultation rights are.

Cooperation obligations, including the seller's obligation to provide data and witnesses — which is a real burden and should be specified.

And the condition precedent itself: expiration of the waiting period, and whether the absence of any pending challenge is a condition. A buyer that must close over an agency lawsuit has a very different risk than one that need not.

What to tell the client

One: the deal will be judged on your own documents. Strategic plans, board decks, deal models, and executive emails, produced with the initial filing under 16 C.F.R. Part 803 and again in any second request. Find yours before the agency does.

Two: a single overlap can carry the whole transaction. Section 7 reaches harm in any line of commerce in any section of the country. Map the overlaps at the product and geography level, not the corporate level.

Three: the statutory clock is not the real timeline. A contested review with a second request and a timing agreement runs a year or more from signing. Set the outside date, the financing, and the interim covenants accordingly.

Four: second request compliance is a litigation-scale project, and its cost is set in the first three weeks by the negotiated custodian count, date range, and protocol.

Five: bring a real remedy early or not at all. A viable standalone divestiture package with an approved upfront buyer resolves transactions; a thin package offered as an alternative to litigation is declined and signals weakness.

Six: the agency is not the only reviewer. State attorneys general, foreign merger control — some of it suspensory — foreign investment review, and sector regulators each have their own clock. Build one regulatory calendar at signing.

Seven: you remain competitors until the waiting period ends. Gun jumping carries per-day penalties, supports an independent claim under Sherman Act § 1, and tells the reviewing agency that you already think of yourselves as one firm.

Eight: reportability and legality are different questions. A transaction below the § 18a thresholds is unreported, not exempt — and non-reportable and consummated transactions are challenged.

And nine, the one worth repeating: the most valuable antitrust work on any deal is done during diligence, before signing, when the overlaps can still change the price, the structure, and the risk allocation. After signing, you are managing a problem you have already bought.

Gun jumping, in more detail

The waiting period exists so that the parties remain independent competitors until the government has had its look, and violating that independence is a distinct offense with its own penalties.

What the prohibition covers. Until the waiting period expires under 15 U.S.C. § 18a, the buyer may not exercise beneficial ownership or operational control over the target. Coordination on price, output, customers, or territories between still-independent competitors is separately unlawful under Sherman Act § 1, regardless of the pending merger.

The conduct that gets companies in trouble:

The buyer approving or directing the target's pricing, bids, or customer terms.
Joint customer meetings in which the parties present as one company.
Allocating customers, opportunities, or territories "for after closing."
Exchanging current pricing, customer-specific terms, bid information, or forward-looking commercial plans without controls.
Integrating sales forces, consolidating facilities, or transferring employees before closing.
Interim covenants drafted so broadly that routine business decisions require buyer consent.

What is permitted. Ordinary diligence with appropriate protections; integration planning conducted through a clean team; covenants that preserve the business in the ordinary course; and aggregated or historical information exchanged under a protocol.

The clean team, done properly. A defined group — frequently outside advisors plus a small number of employees who are not commercially responsible for the affected products — that receives sensitive information, works on integration analysis, and does not report the underlying data back into the business. Membership, scope, and outputs are documented, and the protocol is written before any information moves.

Interim operating covenants need a second look from antitrust counsel. A consent right over ordinary-course pricing decisions is a control right, whatever the merger agreement calls it.

The exposure is real. Civil penalties accrue per day for premature control, and the conduct can support an independent Sherman Act claim. It also, practically, hands the reviewing agency evidence that the parties viewed themselves as one firm — which is not the impression a party arguing that the market is competitive wants to create.

The enforcement problem is enthusiasm, not comprehension. Business teams excited about a transaction begin acting like one company because it is efficient. Train them, write the protocol down, and give the deal team a single point of contact who can answer "can we do this" in an hour.

The reportability question, briefly

Before any of the substance, a threshold: is the transaction reportable at all?

Section 7A and the rules at 16 C.F.R. Part 801 impose notification obligations on acquisitions meeting statutory tests keyed to the size of the transaction and, for smaller deals, the size of the parties — with thresholds adjusted annually. A filing fee applies on a sliding scale, and the parties allocate it by agreement.

The complications are in the rules, not the statute.

Aggregation. Voting securities already held are aggregated with those to be acquired, so a series of small purchases can cross a threshold that no single purchase would.

Who is the acquiring person. The ultimate parent entity, not the acquiring subsidiary — which for fund structures, family holdings, and management vehicles requires actual analysis rather than an organizational chart.

Asset deals and partial acquisitions, including acquisitions of non-corporate interests, follow their own valuation and coverage rules.

Exemptions exist and are technical: ordinary-course acquisitions of goods, certain real property transactions, acquisitions of foreign assets or issuers below defined sales and asset thresholds, and — frequently misapplied — the investment-only exemption for acquisitions of 10% or less made solely for investment. "Solely for investment" is narrower than it sounds and does not survive board representation or an intent to influence management.

Failure to file is expensive. Civil penalties accrue per day of noncompliance, and the agencies have pursued late filings, including by individuals acquiring shares in their own employers.

The practical instruction. Run reportability early, in writing, and re-run it when the deal structure changes — because a restructured transaction can become reportable when the original was not, and the discovery usually comes late.

And note that reportability and legality are different questions. A transaction below the thresholds is not exempt from Section 7; it is merely unreported. The agencies challenge non-reportable transactions, including consummated ones, and increasingly say so.

Screening a deal before it is signed

The most valuable antitrust work on a transaction happens during diligence, and it is cheap.

Map the overlaps, product by product and geography by geography. Not at the corporate level — Section 7 reaches harm in any line of commerce in any section of the country, so a national deal can be challenged on a single niche or a single metropolitan area. Build the overlap matrix from the parties' own revenue data.

Estimate shares honestly. Using third-party market data where it exists, and the parties' own competitive intelligence where it does not — and recognizing that the agency will use the parties' documents, which frequently describe narrower markets than the parties' lawyers would.

Identify the closest competitor question. For each overlap, who does each party actually lose deals to, and in what order? Win-loss data, bid records, and sales force reporting answer this better than share statistics, and they are what the unilateral effects analysis turns on.

Screen the non-horizontal theories too. Does either party supply the other's competitors? Would the combination give access to rivals' competitively sensitive information? Is the target a nascent competitor or a recent entrant? Is this the latest in a series of acquisitions that would be assessed cumulatively?

Run the document assessment before signing, per the discussion above. Finding the problem documents during diligence changes the price, the risk allocation, and the deal structure; finding them in a second request changes only the outcome.

Then price the risk in the agreement. The efforts covenant, the divestiture cap, the outside date, and the reverse termination fee should all be set by this analysis rather than by precedent. A transaction with a clear overlap and a hell-or-high-water covenant is a different deal from the same transaction with a capped divestiture obligation, and the difference is worth real money.

And be willing to say the deal has a problem. Counsel who identifies a genuine Section 7 issue during diligence and says so plainly saves the client the cost of a year of review and a failed transaction — which is a less popular conversation than the alternative and a considerably more valuable one.

Running the second request response

Compliance is a project, and the variables that control its cost and duration are settled in the first three weeks.

Negotiate the scope, hard and immediately. Custodian count is the dominant cost driver, followed by date range and data specifications. Agencies expect this negotiation and generally accommodate reasoned proposals — a list of 40 custodians is an opening position, and reducing it to 15 with a documented explanation of each person's role is ordinary practice, not obstruction.

Agree the protocol in writing: search terms or a technology-assisted review methodology with validation, de-duplication and threading, family production rules, privilege log format, and the production schedule. Getting the protocol agreed before review begins prevents a re-do.

Staff it as a litigation matter. A document review team, a project manager, e-discovery vendors, and — critically — company personnel who can explain the data. The structured data specifications frequently require the finance and IT teams more than the lawyers, and those people have day jobs.

Do not underestimate the narrative responses. The interrogatory-style specifications asking the company to describe its markets, its competitors, its pricing, and its plans are answered by counsel with the business, and they become admissions. Draft them with the same care as a pleading.

Run the substantive campaign in parallel, not after. Economic analysis, customer outreach, and the affirmative story should be developing while review proceeds. Parties that complete compliance and only then begin persuading have wasted the months when the staff's view was still forming.

Meet the staff early and often. The line attorneys and economists form views during compliance. A party that has explained its business, walked through the market, and offered data is in a different position than one that appears at certification with a brief.

Certify carefully. Substantial compliance is the parties' own certification and it restarts the clock. Certify too early and the agency may dispute compliance, which stops the clock and damages credibility; certify late and the deal slips. Confirm the position with the staff before filing the certification.

And decide about the timing agreement before you certify, because the agency will ask, and the answer determines whether the next phase is a negotiation or a race to a lawsuit.

The other reviewers

An antitrust clearance is not the only regulatory gate, and deals fail on the ones nobody scheduled.

State attorneys general have independent authority under state antitrust law and under 15 U.S.C. § 26, and they have become materially more active. They frequently participate in the federal investigation, sometimes sue independently, and occasionally challenge transactions the federal agencies cleared. A transaction with concentrated effects in one or two states should assume state engagement and should brief those offices deliberately rather than reactively.

Foreign merger control. Most substantial transactions require notification in several jurisdictions, each with its own thresholds, timelines, and substantive standards. Some are suspensory — the deal cannot close until cleared — and a single suspensory jurisdiction sets the closing date regardless of where the commercial center of gravity lies. Map the filings at signing, and understand that the analysis in one jurisdiction can be used against you in another; submissions should be consistent, and they are compared.

Foreign investment review. Where the buyer has foreign ownership or the target holds critical technology, sensitive data, or covered real estate, national security review is a separate process with its own timeline, its own mitigation agreements, and its own ability to block a transaction the antitrust agencies would clear.

Sector regulators. Communications, energy, banking, insurance, transportation, healthcare facility licensure, and defense industrial base reviews each have their own approvals, their own public interest standards, and their own clocks. Several apply a broader standard than competition alone.

And the practical instruction. Build a single regulatory calendar at signing that shows every filing, its trigger, its expected timeline, whether it is suspensory, and who owns it. Transactions fail because a filing nobody scheduled became the long pole — and because the outside date in the merger agreement was set by reference to the antitrust review while a foreign suspensory clearance was still running.

The documents, again

Return to where this article started, because it is where these cases are decided.

What the agency will read. Board presentations. Strategic plans. Deal models and synergy cases. Market and competitor analyses. Pricing studies. Emails between executives about why the deal makes sense. Documents from the ordinary course — § 18a and the rules at 16 C.F.R. Part 803 require production of specified categories of documents analyzing the transaction with the initial filing, before any second request.

The documents that cause problems say things like: this acquisition takes out our closest competitor; without them we could finally raise price; they are the only reason we cannot hold the line on discounts; this consolidates the market. Executives write these sentences because they are describing business reality, not because they are describing a violation — and the agency reads them as admissions.

What to do about it, and what not to do.

Do train. Executives at companies that acquire regularly should understand that ordinary-course strategic documents are produced to antitrust agencies, and should describe competitive dynamics accurately rather than dramatically. Accurate description is not evasion; a market with eight credible competitors should be described that way.

Do run a document assessment before signing. Search the likely custodians for the likely themes. Find the bad documents before the agency does, understand them, and build the explanation. A document that has context is a manageable problem; one discovered in a second request production is not.

Do not clean the file. Deleting or altering documents after a transaction is contemplated is obstruction, it is discovered, and it converts a civil merger review into something else entirely. The instruction runs the other way: preserve early, broadly, and verifiably.

And do not write the memorandum explaining that the bad email did not mean what it says. That memorandum is produced too.